ARDS Diagnosis and Management

Introduction to ARDS Mimics

The European Respiratory Society suggests that establishing a diagnostic protocol to identify treatable diseases that mimic ARDS is crucial, as these conditions require specific therapies rather than standard ARDS management 1, 2
ARDS mimics, including diffuse interstitial acute lung diseases, diffuse pulmonary infections, and drug/chemical-induced diffuse lung disease, have distinct pathophysiology requiring specific treatment 2

A detailed exposure history, including recent medications, vaping, occupational exposures, and travel history, is essential for identifying potential ARDS mimics 2
Infectious workup, including bronchoalveolar lavage with comprehensive cultures, viral panels, fungal studies, and consideration of endemic infections, is critical for diagnosing ARDS mimics 2, 4
Immunologic evaluation, including autoimmune serologies and eosinophil counts, should be considered if clinical suspicion exists 2
Cardiac assessment, including echocardiography and hemodynamic monitoring, is necessary to exclude cardiogenic pulmonary edema 3

The European Respiratory Society recommends that specific treatment should be initiated immediately based on the underlying diagnosis of the ARDS mimic 2
Drug-induced lung injury should be treated by withdrawing the offending agent 2
Infectious etiologies should be treated with targeted antimicrobial therapy 2
Immunologic conditions should be treated with corticosteroids or other immunosuppression 2
Cardiogenic pulmonary edema should be treated with diuresis, vasodilators, and hemodynamic optimization rather than conservative fluid strategy 3

The American Thoracic Society recommends lung-protective ventilation with tidal volumes 4-8 ml/kg predicted body weight and plateau pressure ≤30 cmH₂O for true ARDS 5, 4
Conservative fluid management should be used to minimize pulmonary edema while maintaining organ perfusion 3
Prone positioning should be used for >12 hours daily for severe ARDS (PaO₂/FiO₂ <100 mmHg) 5, 4
Higher PEEP should be used in moderate to severe ARDS without prolonged recruitment maneuvers 5, 4
Corticosteroids should be considered in selected patients, particularly with fibroproliferation 1, 5

The European Respiratory Society warns that applying conservative fluid management to cardiogenic pulmonary edema may delay appropriate diuresis 3
Missing drug-induced lung injury allows continued exposure to the causative agent 2
Failing to identify treatable infections results in inadequate antimicrobial coverage 2
Including ARDS mimics in clinical trials without additional diagnostic testing contaminates study populations and may obscure treatment effects 1, 2